Quantitative x-ray computed tomography peritoneography in malignant peritoneal mesothelioma patients receiving intraperitoneal chemotherapy

Annals of Surgical Oncology

Volumn 20, Issue 3 SUPPL., 2013, Pages

  Leinwand, Joshua C ^a   Zhao, Binsheng ^a   Guo, Xiaotao ^a   Krishnamoorthy, Saravanan ^a   Qi, Jing ^a   Graziano, Joseph H ^a   Slavkovic, Vesna N ^a   Bates, Gleneara E ^a   Lewin, Sharyn N ^a   Allendorf, John D ^a   Chabot, John A ^a   Schwartz, Lawrence H ^a   Taub, Robert N ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ANTINEOPLASTIC AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; CANCER CHEMOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTED TOMOGRAPHY PERITONEOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MALE; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MORTALITY; OVERALL SURVIVAL; PERITONEUM MESOTHELIOMA; VERY ELDERLY; YOUNG ADULT; FOLLOW UP; INTRAPERITONEAL DRUG ADMINISTRATION; LUNG NEOPLASMS; MESOTHELIOMA; NEOPLASM, RESIDUAL; PERITONEAL NEOPLASMS; PROGNOSIS; RADIOGRAPHY; REGIONAL PERFUSION; RETROSPECTIVE STUDY; SURVIVAL RATE; TISSUE DISTRIBUTION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CISPLATIN; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; INJECTIONS, INTRAPERITONEAL; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; NEOPLASM, RESIDUAL; PERITONEAL NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TISSUE DISTRIBUTION; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 84892821060     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-013-2976-8     Document Type: Article

References (37)

1. Dedrick RL, Myers CE, Bungay PM, DeVita VT. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978;62(1):1-11.
2. Markman M. Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol. 2003;4(5):277-83.
3. Howell SB, Pfeifle CL, Wung WE, et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med. 1982;97: 845-51.
4. Casper ES, Kelsen DP, Alcock NW, Lewis JL. Ip cisplatin in patients with malignant ascites: pharmacokinetic evaluation and comparison with the iv route. Cancer Treat Rep. 1983;67:235-8.
5. Pretorius RG, Hacker NF, Berek JS, et al. Pharmacokinetics of Ip cisplatin in refractory ovarian carcinoma. Cancer Treat Rep. 1983;67:1085-92.
6. Lopez JA, Krikorian JG, Reich SD, Smyth RD, Lee FH, Issell BF. Clinical pharmacology of intraperitoneal cisplatin. Gynecol Oncol. 1985;20:1-9.
7. Elferink F, van der Vijgh WJ, Klein I, Bokkel Huinink WW, Dubbelman R, McVie JG. Pharmacokinetics of carboplatin after intraperitoneal administration. Cancer Chemother Pharmacol. 1988;21:57-60.
8. Fujiwara K, Markman M, Morgan M, Coleman RL. Intraperitoneal carboplatin-based chemotherapy for epithelial ovarian cancer. Gynecol Oncol. 2005;97:10-5.
9. Markman M, Rowinsky E, Hakes T, et al. Phase I trial of intraperitoneal Taxol: a Gynecologic Oncology Group study. J Clin Oncol. 1992;10:1485-91.
10. Francis P, Rowinsky E, Schneider J, Hakes T, Hoskins W, Markman M. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group Pilot Study. J Clin Oncol. 1995;13:2961-7.
11. Markman M. Intraperitoneal therapy for treatment of malignant disease principally confined to the peritoneal cavity. Crit Rev Oncol Hematol. 1993;14:15-28.
12. Markman M, Howell SB, Lucas WE, Pfeifle CE, Green MR. Combination intraperitoneal chemotherapy with cisplatin, cytarabine, and doxorubicin for refractory ovarian carcinoma and other malignancies principally confined to the peritoneal cavity. J Clin Oncol. 1984;2:1321-6.
13. Markman M, Hakes T, Reichman B, et al. Intraperitoneal cisplatin and cytarabine in the treatment of refractory or recurrent ovarian carcinoma. J Clin Oncol. 1991;9:204-10.
14. Muggia FM, Groshen S, Russell C, et al. Intraperitoneal carboplatin and etoposide for persistent epithelial ovarian cancer: analysis of results by prior sensitivity to platinum-based regimens. Gynecol Oncol. 1993;50:232-8.
15. Miyagi Y, Fujiwara K, Kigawa J, et al. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin-a Sankai Gynecology Study Group (SGSG) study. Gynecol Oncol. 2005;99(3):591-6.
16. Dunnick NR, Jones RB, Doppman JL, Speyer J, Myers CE. Intraperitoneal contrast infusion for assessment of intraperitoneal fluid dynamics. Am J Roentgenol. 1979;133(2):221-3.
17. Muggia FM, LePoidevin E, Jeffers S, Russell C, Boswell W, Morrow CP, Curtin J, Schlaerth J. Intraperitoneal therapy for ovarian cancer: analysis of fluid distribution by computerized tomography. Ann Oncol. 1992;3(2):149-54.
18. Hughes PM, Zammit-Maempel I, Murphy D. Computed tomographic assessment of intraperitoneal fluid distribution prior to intraperitoneal chemotherapy for ovarian cancer. Br J Radiol. 1992;65(772):295-7.
19. Dawson S, Hicks RJ, Johnston V, et al. Intraperitoneal distribution imaging in ovarian cancer patients. Intern Med J. 2009;41:167-71.
20. Barlin JN, Bristow RE, Bleich K, Giuntoli RL, Thompson S, Diaz-Montes TP. Computed tomographic peritoneography prior to intraperitoneal chemotherapy in advanced Müllerian cancer: a pilot study. Clin Imaging. 2010;34(3):191-5.
21. Sugimura K, Okizuka H, Kaji Y, Ishida T, Iwanari O, Kitao M. Prediction of effectiveness of intraperitoneal chemotherapy by intraperitoneal scintigraphy in patients with advanced ovarian carcinoma. Clin Nucl Med. 1994;19(7):600-3.
22. Price B, Ware A. Time trend of mesothelioma incidence in the United States and projection of future cases: an update based on SEER data for 1973 through 2005. Crit Rev Toxicol. 2009; 39(7):576-88.
23. Carbone M, Ly BH, Dodson RF, Pagano I, Morris PT, Dogan UA, Gazdar AF, Pass HI, Yang H. Malignant mesothelioma: facts, myths, and hypotheses. J Cell Physiol. 2012;227(1):44-58.
24. Hassan R, Alexander R. Nonpleural mesotheliomas: mesothelioma of the peritoneum, tunica vaginalis, and pericardium. Hematol Oncol Clin North Am. 2005;19(6):1067-87, vi.
25. Damhuis RA, Schroten C, Burgers JA. Population-based survival for malignant mesothelioma after introduction of novel chemotherapy. Eur Respir J. 2012;40(1):185-9.
26. Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol. 2003;21(24):4560-7.
27. Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27(36):6237-42.
28. Kluger MD, Taub RN, Hesdorffer M, Jin Z, Chabot JA. Twostage operative cytoreduction and intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma: Operative morbidity and mortality in phase I and II trials. Eur J Surg Oncol. 2010;36(10):997-1003.
29. Hesdorffer ME, Chabot JA, Keohan ML, et al. Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma. Am J Clin Oncol. 2008;31(1):49-54.
30. Shen P, Levine EA, Hall J, et al. Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg. 2003;138(1):26-33.
31. Mohamed F, Sugarbaker PH. Peritoneal mesothelioma. Curr Treat Options Oncol. 2002;3(5):375-86.
32. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16(1):31-41.
33. Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987;317(17):1098.
34. Flessner MF. The transport barrier in intraperitoneal therapy. Am J Physiol Renal Physiol. 2005;288(3):F433-42.
35. Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2011;11:CD005340.
36. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006; 354(1):34-43.
37. Walker JL, Armstrong DK, Huang HQ, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2006;100(1):27-32.